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This study reports improved mutasynthetic
approaches for the production of aminocou-
marin antibiotics. Previously, the mutasynthetic
production of aminocoumarins with differently
substituted benzoyl moieties was limited by
the substrate specificity of the amide synthe-
tase CloL. We expressed two amide synthe-
tases with different substrate specificity, CouL
and SimL, in appropriately engineered pro-
ducer strains. After feeding of precursor an-
alogs that were not accepted by CloL, but by
SimL or CouL, a range of aminocoumarins, un-
attainable in our previous experiments, was
produced and isolated in preparative amounts.
Further, we developed a two-stage mutasyn-
thesis procedure for the production of hybrid
antibiotics that showed the substitution pattern
of novobiocin in the aminocoumarin moiety and
that of clorobiocin in the deoxysugar moiety.
The substitution pattern of the benzoyl moi-
ety was determined by external addition of
an appropriate precursor. Twenty-five ami-
nocoumarin compounds were prepared by
these methods, and their structures were eluci-
dated with mass and 1H-NMR spectroscopy.
INTRODUCTION
Mutasynthesis, i.e., the feeding of synthetic precursor an-
alogs to mutants of microbial producer strains of natural
products, is an important and powerful tool for drug dis-
covery and lead optimization. However, this technique
has three principal limitations [1]: (1) the range of precur-
sors that can be incorporated into the final molecule is
limited by the substrate specificity of the biosynthetic en-
zymes; (2) usually, only the structural features generated inChemistry & Biology 14, 95the early steps of the biosynthesis can be modified; and (3)
the range of precursors that can be taken up into the pro-
ducing cells is limited. Here, we present examples of how
the first two of these limitations, and thereby the structural
diversity of compounds generated by mutasynthesis, can
be significantly expanded by appropriate metabolic engi-
neering of the employed mutant strains, as well as by
utilization of two-stage feeding procedures.
The aminocoumarin antibiotics novobiocin, clorobiocin,
coumermycin A1, and simocyclinone D8 (Figure 1) are pro-
duced by different Streptomyces strains. These com-
pounds are potent inhibitors of bacterial gyrase [2]. Novo-
biocin has been licensed in the United States under the
name Albamycin for the treatment of infections with
Gram-positive bacteria in humans.
All aminocoumarin antibiotics contain a 3-amino-4,7-
dihydroxycoumarin moiety (= Ring B; Figure 1). This is
substituted at position 8 by a chlorine atom in the case of
clorobiocin and simocyclinone D8, or by a methyl group
in the case of novobiocin and coumermycin. The amino-
coumarin moiety is attached, via an amide bond, to struc-
turally very different acyl moieties (Figure 1). In novobiocin,
clorobiocin, and coumermycin A1, the aminocoumarin
moiety is furthermore glycosidically linked to a deoxysugar.
Our group has cloned and sequenced the biosynthetic
gene clusters of all four aminocoumarin antibiotics, and
the functions of most of the genes contained therein
were elucidated [3, 4]. These findings now form the basis
for the development of new aminocoumarin derivatives by
metabolic engineering and chemoenzymatic synthesis [3].
A mutant strain of the clorobiocin producer, which was
defective in the gene for the prenyltransferase CloQ, was
successfully used for mutasynthesis experiments. The
prenyltransferase CloQ is required for the biosynthesis
of the prenylated 4-hydroxybenzoate moiety (= Ring A)
of clorobiocin (Figure 1). Feeding of different synthetic
Ring A analogs to the cloQ-defective mutant resulted in
the formation of several new aminocoumarin derivatives
with modified substitution patterns [5].
However, this method was limited by the substrate
specificity of CloL. In clorobiocin biosynthesis, the amide5–967, August 2007 ª2007 Elsevier Ltd All rights reserved 955
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(A) Structure and biosynthesis of novobiocin.
(B) Structures of simocyclinone D8, coumermycin A1, and clorobiocin.
The amide bonds generated by the amide synthetases NovL, SimL, CouL, and CloL are marked in gray.synthetase CloL attaches the externally added Ring A
analog to the 3-amino group of the aminocoumarin ring.
As shown by Galm et al. [5], CloL accepts different Ring
A analogs with very different efficiency in vitro. The prod-
uct yields in the amide synthetase reaction in vitro cor-
related with the yields of the respective aminocoumarin
antibiotics obtained in vivo in mutasynthetic feeding
experiments [5]. Compounds that were poor substrates
of CloL in vitro, such as 3,5-dimethyl-4-hydroxybenzoic
acid, did not lead to the formation of aminocoumarin anti-
biotics in mutasynthesis experiments.
The aim of the present study was to expand the range of
new aminocoumarin antibiotics producible from mutasyn-
thesis experiments, by using metabolic engineering of the
producer strains. For this purpose, we expressed, in an
appropriate mutant of the producer strain, the amide syn-
thetases CouL or SimL, involved in the biosynthesis of cou-
mermycin A1 and simocyclinone D8. Both enzymes utilize
completely different acyl substrates than CloL (Figure 1).956 Chemistry & Biology 14, 955–967, August 2007 ª2007 ElseIn a second approach, we attempted to generate hybrid
antibiotics, i.e., aminocoumarin antibiotics that contain
structural features of both clorobiocin and novobiocin.
For this purpose, we developed a two-step feeding strat-
egy that successively uses mutants of the novobiocin and
the clorobiocin producer strains.
RESULTS
Utilization of Different Amide Synthetases
to Overcome Limitations of Substrate Specificity
As may be expected from the structures of clorobiocin,
novobiocin, coumermycin A1, and simocyclinone D8 (Fig-
ure 1), the substrate specificities of the amide synthetases
CloL and NovL are similar to each other, whereas both
CouL and SimL accept many substrates that are not con-
verted by any of the other three enzymes [5–8]. Therefore,
the genes couL and simL were cloned into the expression
vector pUWL201, which contains the constitutive ermE*vier Ltd All rights reserved
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respectively.
In cosmid clo-BG1, which harbors the complete biosyn-
thetic gene cluster of clorobiocin, the gene cloL, coding
for the genuine amide synthetase, and the gene cloQ, re-
quired for Ring A biosynthesis [10], were inactivated by l
RED-mediated recombination, resulting in cosmid clo-
CA5. This cosmid was integrated into the genome of
Streptomyces coelicolor M512 [11], resulting in the strain
S. coelicolor(clo-CA5). The genotype of the resulting
mutant was confirmed by Southern blot (Figure 2). As ex-
pected, cultivation and HPLC analysis of S. coelicolor(clo-
CA5) showed that no clorobiocin was produced, while in-
tegration of an intact clorobiocin cluster (i.e., clo-BG1) into
S. coelicolor M512 resulted in a strain producing approx-
imately 35 mg/ml clorobiocin [11]. Since in S. coelicolor-
(clo-CA5) the amide synthetase gene cloL had been
deleted, this strain could not produce clorobiocin even
when the prenylated 4-hydroxybenzoate moiety (= Ring
A) was added externally. However, when the couL expres-
sion plasmid pMS91 or the simL expression plasmid pSH2
were introduced into S. coelicolor(clo-CA5), external feed-
ing of Ring A readily resulted in the formation of clorobio-
cin (data not shown). This was expected, as the amide
synthetases CouL and SimL can accept Ring A as a
substrate [5, 7, 8].
In order to investigate whether the introduction of couL
and simL could expand the range of aminocoumarin anti-
biotics accessible from mutasynthesis experiments, we
added synthetic Ring A analogs to four different strains.
Three of these strains were obtained from S. coelicolor-
(clo-CA5) by transformation with (1) the empty expression
vector pUWL201, with (2) the couL expression plasmid
pMS91, or with (3) the simL expression plasmid pSH2.
The fourth strain was a previously described cloQ-
defective mutant [5, 10] that still contained the genuine
amide synthetase gene cloL. In a first experiment, we
added to these strains 3,5-dimethyl-4-hydroxybenzoic
acid, which is readily accepted by CouL, but is poorly ac-
cepted by the other amide synthetases. The extracts of
the four cultures were investigated by HPLC and by LC-
MS (Figure 3A). The expected new antibiotic, which car-
ries 3,5-dimethyl-4-hydroxybenzoic acid as Ring A analog
(novclobiocin 201, Table 1), was detected only in the
extract of the strain harboring couL, not in the other three
strains.
In a second experiment, we added benzoic acid, which
is accepted by SimL, but is poorly accepted by the other
amide synthetases. In this case, the antibiotic containing
benzoic acid as a Ring A analog was detected only in
the strain harboring simL (Figure 3B). This proved that
the expression of different amide synthetases indeed al-
lowed for the production of aminocoumarin antibiotics
which were unattainable in our previous experiments.
The amide synthetase SimL appears to be especially suit-
able for this approach, as it accepts many substrates that
are poorly utilized by NovL, CloL, or CouL [7, 12], including
4-methylthiobenzoic acid, cinnamic acid, and ferulic acid.
Feeding of these three compounds to S. coelicolor(clo-Chemistry & Biology 14, 955CA5) harboring simL readily gave the expected cloro-
biocin analogs (Table 1). All compounds, including the
products resulting from the feeding of benzoic acid and
3,5-dimethyl-4-hydroxybenzoic acid, were isolated in
preparative amounts, and their structures were confirmed
by 1H-NMR and mass spectrometry (MS) (see Experimen-
tal Procedures).
In four of these five feeding experiments, a minor prod-
uct was formed that showed the same mass as the
respective clorobiocin analog. 1H-NMR spectroscopy
proved that these compounds were structural isomers of
the dominant clorobiocin analogs, carrying the 5-methyl-
pyrrole-2-carboxylic acid esterified to 200-OH instead of
300-OH of the deoxysugar [13]. This type of isomer has
also been observed in previous studies [5].
In the feeding experiments with benzoic acid and 3,5-
dimethyl-4-hydroxybenzoic acid, an additional product
could be isolated by preparative HPLC with suitable sol-
vent systems. Mass spectrometric analysis showed a
mass that was 34 Da lower than that of the respective
clorobiocin analog, consistent with the loss of a chlorine
atom. 1H-NMR spectroscopy showed an additional pro-
ton in the aminocoumarin system, proving that these com-
pounds carry a hydrogen instead of a chlorine atom at
C-80 of the aminocoumarin moiety. Therefore, halogena-
tion of position 80 by Clo-hal had not been carried out
completely, and similar observations had been made in
previous studies [5, 11].
When we fed 4-hydroxybenzoic acid (4-HBA) to S. coe-
licolor(clo-CA5) harboring simL, an 80-chlorinated amino-
coumarin antibiotic as well as the corresponding 80-non-
substituted compound could be isolated. However, MS
and 1H-NMR analysis proved that these two compounds
carried a vanilloyl (i.e., 3-methoxy-4-hydroxybenzoyl) moi-
ety as the Ring A analog, indicating that the externally
added 4-HBA has been hydroxylated and methylated in
position 3. As observed previously [6], small amounts of
these two compounds were formed even without feeding
of 4-HBA, i.e., from an endogenous pathway leading to
vanillic acid.
Hybrid Aminocoumarin Antibiotics from
Two-Stage Mutasynthesis Experiments
In a second series of experiments, we investigated a two-
stage mutasynthesis procedure. In the first stage, Ring A
analogs were fed to a strain with an engineered novobio-
cin biosynthetic gene cluster. This strain (S. coelicolor-
(nov-CA7), see the Experimental Procedures) could form
the 3-amino-4,7-dihydroxycoumarin moiety, attach it to
the externally added Ring A analog (by utilizing NovL as
a catalyst), and methylate the resulting product at position
80 (Figure 4) [14]. However, the strain could not produce
the complete antibiotic, due to defects in Ring A and
deoxysugar biosynthesis. The feeding therefore resulted
in analogs of the aglycon of novobiocin, which is termed
novobiocic acid (Figure 4). The culture extract from this
first mutasynthetic feeding step was subsequently added,
without purification, to a second strain. That strain was
S. coelicolor(clo-CA5), described above, which formed–967, August 2007 ª2007 Elsevier Ltd All rights reserved 957
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Mutasynthetic Production of Modified AminocoumarinsFigure 2. Construction of clo-CA5 and Southern Blot Analysis of the Mutant S. coelicolor(clo-CA5)
(A) Cosmid constructs clo-BG1 (intact) and clo-CA5 (DcloLDcloQ) containing the clorobiocin biosynthetic gene cluster and theVC31 integration func-
tions. T3, T7 = T3, and T7 promoter of the SuperCos1 vector. The cosmid backbone is not to scale.
(B) Schematic representation of site-specific integration of clo-CA5 into the S. coelicolor chromosome. B = BglII restriction site. Fragment sizes
resulting from digestion with BglII are indicated.
(C) Schematic presentation of the cloL and cloQ inactivation and restriction fragment analysis of the modified cosmids. cloLwas replaced by an apra-
mycin cassette that was subsequently excised by restriction enzyme digestion and religated, leaving an in-frame ‘‘scar’’ of 18 nucleotides, resulting in958 Chemistry & Biology 14, 955–967, August 2007 ª2007 Elsevier Ltd All rights reserved
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(A and B) HPLC analysis of culture extracts of different S. coelicolor(clo-CA5) mutants after feeding of (A) 3,5-dimethyl-4-hydroxybenzoic acid
or (B) benzoic acid. The identity of the marked peaks was confirmed by LC-MS as well as by 1H-NMR. Unmarked peaks are metabolites unrelated
to aminocoumarins, as confirmed by LC-MS.the deoxysugar, the 400-methyl group, and the 5-methyl-
pyrrole-2-carbonyl moiety, which is typical of clorobiocin,
and attached them to the novobiocic acid analog (Fig-
ure 4). Therefore, this two-stage procedure led to the for-
mation of hybrid antibiotics that carry structural features of
both novobiocin and clorobiocin.
Five Ring A analogs (Table 2, A compounds), known to
be accepted by the amide synthetase NovL, were sub-
jected to this two-stage mutasynthesis procedure. The re-
sulting aminocoumarin antibiotics were isolated by pre-
parative HPLC, and their structures were elucidated by
1H-NMR and MS.
In all five experiments, the expected aminocoumarin
antibiotics containing the externally added Ring A analog
were obtained. However, when Ring A analogs thatChemistry & Biology 14, 95carried either a bromine atom or a polar side chain with
an amide bond at position 3 were used, the resulting ami-
nocoumarin antibiotics were unexpectedly found to con-
tain a chlorine atom rather than a methyl group at position
80 of the aminocoumarin ring (Table 2, A compounds).
Their structures were unequivocally confirmed by both
1H-NMR and MS (see the Experimental Procedures).
This finding suggests that the novobiocic acid analogs
containing these polar Ring A analogs are poor substrates
of the 80-methyl transferase NovO (Figure 4), but a good
substrate for the halogenase Clo-hal [15], present in
S. coelicolor(clo-CA5). Control experiments proved
that no 80-halogenated compounds were produced by
S. coelicolor(nov-CA7) alone, which does not contain
the halogenase Clo-hal. S. coelicolor(clo-CA5), whichcosmid clo-CA3. In the same way, cloQwas inactivated, resulting in cosmid clo-CA5. This figure is not to scale. M = 1 kb DNA ladder (Invitrogen). DNA
of clo-BG1, clo-CA3, and clo-CA5 were digested with BglII.
(D) Southern blot analysis of the S. coelicolor M512 (S. c.) integration mutant harboring clo-CA5. M = DIG-labeled DNA Molecular Weight Marker VII
(Roche). Genomic DNA was digested with BglII. The DIG-labeled cosmid clo-BG1 was used as a probe.5–967, August 2007 ª2007 Elsevier Ltd All rights reserved 959
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Utilizing the Amide Synthetase Genes couL or simL
Compound Name R1 R2 R3 R4
Novclobiocin 201 Cl OH Pyr
Novclobiocin 202 Cl Pyr OH
Novclobiocin 203 H OH Pyr
Novclobiocin 311a Cl OH Pyr
Novclobiocin 312a Cl Pyr OH
Novclobiocin 313a H OH Pyr
Novclobiocin 371 Cl OH Pyr
Novclobiocin 372 Cl Pyr OH
Novclobiocin 601 Cl OH Pyr
Novclobiocin 602 Cl Pyr OH
Novclobiocin 603 H OH Pyr
Novclobiocin 701 Cl OH Pyr
Novclobiocin 702 Cl Pyr OH
Novclobiocin 731 Cl OH Pyr
couL was used for production of novclobiocin 201, 202, and 203. simL was used for all other experiments.
a These products were already isolated and identified by Freitag et al. [6].does not contain CloQ and CloL, produced these 80-
chlorinated aminocoumarin antibiotics only upon feeding
with 80-unsubstituted novobiocic acid analogs, not
upon feeding with Ring A analogs. This supports the
hypothesis formulated by Pacholec et al. [14] that 80-
desmethyl novobiocic acid may be the genuine substrate
of Clo-hal.
Again, structural isomers containing the 5-methyl-
pyrrole-2-carbonyl moieties at 200-OH rather than 300-OH
were formed in several of these feeding experiments
(Table 2, A compounds).960 Chemistry & Biology 14, 955–967, August 2007 ª2007 ElseUtilization of a Heterologous Amide Synthetase
in Two-Stage Mutasynthesis Experiments
We had shown that both the expression of heterologous
amide synthetases and the utilization of a two-stage pro-
cedure can expand the range of aminocoumarin anti-
biotics accessible from mutasynthesis experiments.
We now attempted to combine these two strategies. For
this purpose, the simL expression plasmid pSH2 was
transformed into strain S. coelicolor(nov-CA7). Subse-
quently, three Ring A analogs, known to be accepted by
the amide synthetase SimL, but to be poorly acceptedvier Ltd All rights reserved
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Mutasynthetic Production of Modified AminocoumarinsFigure 4. Schematic of the Two-Stage Feeding Procedure
See text for explanations.by NovL [7], were fed to this strain (Table 2, B com-
pounds). As described above, the resulting culture ex-
tracts containing novobiocic acid analogs were fed,
without purification, to S. coelicolor(clo-CA5).
In all three experiments, the expected aminocoumarin
antibiotics could be isolated in preparative amounts and
analyzed by 1H-NMR and MS (see the Experimental Pro-
cedures). In the feeding experiment with cinnamic acid,
additionally a compound was isolated that carried a chlo-
rine rather than a methyl group in position 80 (Table 2,
B compounds, novclobiocin 701).
Antibacterial Activity
The antibacterial activity of selected compounds, repre-
senting novclobiocin with different Ring A analogs and car-
rying the pyrrole-2-carboxl group attached to the 3-OH
group of the deoxysugar, were investigated againstStaph-
ylococcus aureus ATCC 43300, a Gram-positive, methicil-
lin-resistant pathogen strain, and Pseudomonas aerugi-
nosa K799/wt, a Gram-negative bacterium (Table 3).
Aminocoumarin antibiotics have been reported to show
poor activity against Gram-negative pathogens, but high
activity against Gram-positive strains, especially against
staphylococci [16]. Correspondingly, Pseudomonas aeru-
ginosa K799/wt was not sensitive to the tested aminocou-
marin derivatives. In contrast to this, Staphylococcus
aureusATCC 43300 was sensitive to all of the tested deriv-
atives. Novclobiocins 217 and 225, which include Ring AChemistry & Biology 14, 95analogs similar to the genuine Ring A, were most active.
Novclobiocins 201, 314, 371, and 701 also showed activi-
ties comparable to that of novobiocin. However, low activ-
ities resulted from a polar side chain in the Ring A analog
(novclobiocin 241) and from the lack of a substituent at po-
sition 8 of the coumarin moiety (novclobiocin 203).
DISCUSSION
In the present study, we demonstrated that limitations of
mutasynthesis experiments can be overcome by exploit-
ing the natural diversity of biosynthetic genes and en-
zymes. Utilizing the amide synthetases SimL and CouL,
which use different substrates than CloL, we could gener-
ate a range of modified aminocoumarins which were not
accessible from our previous mutasynthetic experiments.
For the present experiments, we generated heterolo-
gous producer strains by stable integration of biosynthetic
gene clusters into the genome of Streptomyces coelicolor
M512. The genetic modification of gene clusters by l
RED-mediated recombination [17] and the heterologous
expression of these clusters in the fully sequenced host
S. coelicolor [11] greatly expand the possibilities for muta-
synthetic experiments.
In our mutasynthesis approach, the structure of the
substituted benzoyl moiety of the resulting antibiotic could
be chosen by external addition of the respective Ring A
analog, and the structures of the other parts of the5–967, August 2007 ª2007 Elsevier Ltd All rights reserved 961
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Compound Name R1 R2 R3 R4
A Novclobiocin 217 CH3 OH Pyr
Novclobiocin 218 CH3 Pyr OH
Novclobiocin 225 CH3 OH Pyr
Novclobiocin 226 CH3 Pyr OH
Novclobiocin 241a Cl OH Pyr
Novclobiocin 281a Cl OH Pyr
Novclobiocin 386 CH3 OH Pyr
Novclobiocin 387 CH3 Pyr OH
B Novclobiocin 314 CH3 OH Pyr
Novclobiocin 604 CH3 OH Pyr
Novclobiocin 703 CH3 OH Pyr
Novclobiocin 701 Cl OH Pyr
(A) Compounds obtained without additional amide synthetase.
(B) Compounds obtained with expression of the amide synthetase SimL.
a These compounds were already isolated by Galm et al. [5].molecule could be chosen by use of an appropriately en-
gineered strain. Strains that produce many differently
substituted aminocoumarin and deoxysugar moieties are962 Chemistry & Biology 14, 955–967, August 2007 ª2007 Elavailable from previous work [18–21]. Therefore, the pres-
ent procedure opens a route to a large number of structur-
ally different aminocoumarin antibiotics.sevier Ltd All rights reserved
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panded by two-stage mutasynthesis experiments. In the
first stage, the externally added Ring A analog is attached
to a chosen substituted aminocoumarin, and then, in the
second stage, the resulting culture extract is fed to another
strain that attaches differently substituted deoxysugarmoi-
eties to the aminocoumarin (see Figure 4). We have shown
that such two-stage mutasynthesis experiments can be
performed successfully. The two-stage mutasynthesis
strategy was also combined with the expression of differ-
ent amide synthetases in the first stage, further expanding
the range of accessible antibiotic structures (Table 2, B
compounds). No purification was required between the
first and second stage. As expected, the overall yields of
two-stage experiments were lower than those of one-stage
approaches: by feeding of 10 mg of a given Ring A analog,
up to 4 mg of the respective aminocoumarin antibiotic
could be obtained in one-stage experiments, but only up
to 1 mg could be obtained in two-stage experiments.
SIGNIFICANCE
Our study exemplifies that the efficiency and versatil-
ity of mutasynthesis experiments can be significantly
improved by utilization of the natural diversity of bio-
synthetic genes and enzymes for the generation of
metabolically engineered microbial producer strains
and by utilization of two-stage feeding procedures.
These methods offer the potential to significantly
increase the structural diversity of natural products
obtainable by mutasynthesis experiments in drug
discovery programs.










Novclobiocin 201 0.25 >32
Novclobiocin 203 4 >32
Novclobiocin 217 %0.06 >32
Novclobiocin 225 %0.06 >32
Novclobiocin 241 4 >32
Novclobiocin 281a 1 >32
Novclobiocin 311 1 >32
Novclobiocin 314 0.25 >32
Novclobiocin 371 0.25 >32
Novclobiocin 386 1 >32
Novclobiocin 701 1 >32
Novclobiocin 731 0.5 >32
Antibacterial activity is given as MIC (mg/ml).
a Tested against Staphylococcus aureus ATCC 29213 [16].Chemistry & Biology 14, 95EXPERIMENTAL PROCEDURES
Chemicals
Novobiocic acid was isolated from Streptomyces spheroides AM1T2
[22]; Ring A (3-dimethylallyl-4-hydroxybenzoic acid) was obtained by
hydrolysis of novobiocin [23]; commercially available Ring A analogs
were purchased from Aldrich, Fluka, Lancaster, Merck, and Sigma;
and further substituted benzoic acids were synthesized as described
by Dessoy [24].
Genetic Procedures
Escherichia coliXL1 Blue MRF0 (Stratagene, Heidelberg, Germany), BW
25113 [25], and ET 12567 [26] were used for cloning. The REDIRECT
technology kit for PCR targeting was obtained from Plant Bioscience
Limited (Norwich, UK). Standard methods for DNA isolation and manip-
ulation were performed as described by Sambrook et al. [27] and by
Kieser et al. [28]. Isolation of cosmids and plasmids was carried out with
ion-exchange columns (Nucleobond AX kit; Macherey-Nagel). Geno-
mic DNA was isolated from Streptomyces strains by lysozyme treat-
ment and phenol/chloroform extraction described by Kieser et al. [28].
Southern blot analysis was performed on a Hybond-N nylon mem-
brane (Amersham, Braunschweig, Germany) with digoxigenin-labeled
probes by using the DIG high-prime DNA-labeling kit (Roche Molecular
Biochemicals).
Construction of Plasmids pMS91 and pSH2
The E. coli-Streptomyces shuttle vector pUWL201, containing the
ermE* promoter [9], was used for the construction of the expression
plasmids pMS91 and pSH2.
For the construction of pMS91, couL was amplified by PCR. A Hin-
dIII site was introduced before the start codon by using primer cumG1
(50-CCGCTGCCCAAGCTTGAGTGCCTC-30). At the C terminus, an
XbaI restriction site was introduced after the stop codon by using
primer cumG2 (50-CGGGCAGGCTCTAGAACAGCACTC-30 ). Bold let-
ters represent the restriction sites. The resulting PCR fragment was
digested with HindIII and XbaI and was subsequently cloned into the
same sites of pUWL201 to give pMS91.
For the construction of pSH2, the gene simL was isolated by restric-
tion digest with NotI from cosmid VII-8g, containing a part of the simo-
cyclinone biosynthetic gene cluster of S. antibioticus Tu¨ 6040 [4], and
was cloned into pcDNA2.1 (Invitrogen, La Jolla, California, USA), re-
sulting in pTLsimLfori. The correct orientation of simL was confirmed.
pTLsimLfori was digested with XbaI and HindIII, and the fragment con-
taining simL was cloned into pUWL201 to give pSH2.
Inactivation of cloL and cloQ in Cosmid clo-BG1
and Heterologous Expression
In cosmid clo-BG1 [11], first cloL and then cloQwere replaced, through
l RED-mediated recombination, with an apramycin-resistance
(aac(3)IV) cassette that was flanked by XbaI and SpeI recognition sites.
For replacement of cloL, the cassette was generated by PCR by using
pUG019 [11] as template and the primers cloL_for (50-AGCGGAAG
TACCTCTACTTCGCGAAAGGTAGTCACTGGTGATTCCGGGGATC
TCTAGATC-30) and cloL_rev (50-CATCGAATGACTCACCTCACC
TGTCCACCAGCACGTCCGGACTAGTCTGGAGCTGCTTC-30). Bold
letters represent the homologous extensions to the DNA regions im-
mediately upstream and downstream of cloL. Underlined letters indi-
cate the XbaI and SpeI restriction sites. PCR amplification was per-
formed in 50 ml volume with 50 ng template, 0.2 mM dNTPs, 50 pmol
of each primer, and 5% (v/v) DMSO with the Expand High Fidelity
PCR system (Roche Molecular Biochemicals): denaturation at 94C
for 2 min, then 10 cycles with denaturation at 94C for 45 s, annealing
at 50C for 45 s, and elongation at 72C for 90 s, followed by 15 cycles
with annealing at 55C for 45 s, and the last elongation step at 72C
for 5 min. The PCR product was introduced by electroporation into
E. coli BW25113/pIJ790 harboring cosmid clo-BG1 [17]. The resulting
modified cosmid clo-CA2 was isolated, transformed into the nonme-
thylating strain E. coli ET12567, reisolated, and digested with XbaI5–967, August 2007 ª2007 Elsevier Ltd All rights reserved 963
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overnight at 4C gave the cosmid clo-CA3.
The apramycin-resistance cassette for replacement of cloQ was
generated by PCR amplification with the primers cloQ_for (50-GG
CGCGCCCATTGCTCACCGTCTTACCGACACCGTCCTTATTCCGG
GGATCTCTAGATC-30) and cloQ_rev (50-CCCATGGTCGATTCCGT
GTGTTGGTGAAGTGCGCGCAGACTAGTCTGGAGCTGCTTC-30) and
the same template and conditions as described above. The PCR prod-
uct was introduced by electroporation into E. coli BW25113/pIJ790
harboring cosmid clo-CA3. Again, the modified cosmid was isolated,
and the resistance cassette was removed with XbaI and SpeI. Religa-
tion gave the cosmid clo-CA5.
The cosmid clo-CA5 isolated from E. coli ET12567 was introduced
into S. coelicolor M512 by PEG-mediated protoplast transformation
[28]. Clones resistant to kanamycin were selected, and integration of
clo-CA5 into the genome was confirmed by Southern blot analysis
(Figure 2).
Transformation with the Plasmids pMS91 or pSH2
Transformation of the different integration mutants was carried out by
PEG-mediated protoplast transformation [28].
Inactivation of novQ in the Cosmid nov-BG1
and Heterologous Expression
In cosmid nov-BG1 [11], novQ was inactivated by a similar strategy to
that described above. The apramycin-resistance cassette was gener-
ated by PCR with the primers novQ_P01f (50-ACCGGTAATTC
ACTGTGAGTTGATCACGGAGGAATTCATGATTCCGGGGATCTCTA
GATC-30) and novQ_P02rev (50-AGTCGTCTCCGGGCATGTTCGC
CAGAGCCTCGCTCATCGACTAGTCTGGAGCTGCTTC-30). The PCR
product was introduced by electroporation into E. coli BW25113/
pIJ790 harboring cosmid nov-BG1 [17]. The modified cosmid was iso-
lated and the apramycin-resistance cassette was excised to give the
cosmid nov-CA7.
Cosmid nov-CA7 isolated from E. coli ET12567 was introduced into
S. coelicolor M512 [28]. Clones resistant to kanamycin were selected,
and integration of nov-CA7 into the genome was confirmed by South-
ern blot analysis (data not shown). Feeding of Ring A to this strain re-
sulted in the accumulation of novobiocic acid, but not of novobiocin,
showing that the deoxysugar biosynthesis, encoded by novSTUVW
situated downstream of novQ (Figure 2), had been abolished, presum-
ably due to downstream effects. Since the inactivation of novQ had
been carried out by in-frame deletion, the precise nature of the down-
stream effects was not clear. To our surprise, novQ inactivations utiliz-
ing four different strategies resulted in this same phenotype: (1) re-
placement of the novQ gene with an apramycin-resistance cassette
in the wild-type producer Streptomyces spheroides; (2) in-frame dele-
tion of the entire coding sequence of novQ between the start codon
and the stop codon, and expression of this modified novobiocin cluster
in the heterologous host Streptomyces coelicolor M512; (3) repetition
of experiment (2), but leaving the last codon of novQ (CGA) before the
stop codon intact in order not to affect the presumed translational cou-
pling between novQ and novR (CGATGAGC; bold letters indicate the
last two codons of novQ; underlined letters indicate the first two co-
dons of novR); (4) introduction of a frameshift into novQ by deletion
of a single base (position 19059 in accession number AF170880). All
four mutant strains produced, upon feeding of Ring A, the aglycon no-
vobiocic acid, but not the glycoside novobiocin; therefore, all four inac-
tivation methods affected the downstream deoxysugar biosynthesis
genes novSTUVW. Our experiments did not allow us to determine
whether this effect was due to termination of transcription, altered
mRNA stability, termination of translation, disrupted protein-protein in-
teractions, or other factors. However, this result made the originally
planned, separate inactivation of the deoxysugar biosynthesis genes
unnecessary. HPLC-MS analysis of the products obtained by feeding
of Ring A analogs to strain S. coelicolor M512(nov-CA7), generated by
inactivation strategy (3), proved that these products represented
the desired aglyca. HPLC-MS and NMR analysis of the products of964 Chemistry & Biology 14, 955–967, August 2007 ª2007 Elsthe two-stage feeding procedure proved that these represented the
desired glycosides, carrying the pyrrole-2-carboxyl moiety typical of
clorobiocin.
Production of Aminocoumarin Antibiotics by
One- and Two-Stage Mutasynthesis Experiments
The strains were cultured as described previously [5]. For one-stage
mutasynthesis experiments, 1 mg of the Ring A analog was dissolved
in 200 ml ethanol and added to 80 ml of the culture at the time of inoc-
ulation of the production medium, followed by cultivation for 7–10 days
at 33C and 210 rpm.
For analytic purposes, 1 ml bacterial culture was acidified with HCl
to pH 4 and extracted twice with an equal volume of ethyl acetate. After
evaporation of the solvent, the residue was redissolved in 100 ml meth-
anol. After centrifugation, 80 ml supernatant was analyzed by HPLC
with an Agilent Eclipse XDB-C18 column (5 mm, 150 3 4.6 mm) at
a flow rate of 1 ml min1. A linear gradient from 40% to 100% solvent
B (solvent A = 50:49:1 MeOH:H2O:HCOOH; solvent B = 99:1 MeOH:
HCOOH) over 28 min was used. UV detection was carried out at
340 nm. Authentic clorobiocin (Aventis) was used as standard.
For preparative isolation of the products, cultivation was carried out
as described above, by using a total culture volume of 800 ml. The
antibiotics were isolated as described previously [5].
For two-stage mutasynthesis experiments, S. coelicolor(nov-CA7)
was precultivated in CDM medium [29] for 3–4 days and then used
to inoculate ten flasks, each containing 50 ml CDM production me-
dium. At the time of inoculation, 1 mg of the Ring A analog, dissolved
in 200 ml ethanol, was added to each flask, followed by cultivation for
7–10 days at 30C and 210 rpm. The culture was adjusted to pH 4 with
hydrochloric acid and extracted twice with an equal volume of ethyl ac-
etate. The organic layer was evaporated to dryness. The amount of the
aglycon (= novobiocic acid analog) contained in this extract was deter-
mined by HPLC, and the extract was dissolved in an appropriate vol-
ume of ethanol to obtain a final concentration of 1 mg aglycon in
200 ml ethanol. A total of 200 ml of this solution was added, at the
time of inoculation, to 80 ml of a culture of S. coelicolor(clo-CA5) in dis-
tillers solubles production medium as described previously [5]. The to-
tal culture volume varied between 160 ml and 560 ml. After cultivation
for 7–10 days at 33C and 210 rpm, the preparative isolation and puri-
fication of the products were carried out as described above.
Structure Elucidation
Positive electrospray ionisation (ESI) mass spectra were obtained from
a Finnigan TSQ Quantum instrument (electrospray voltage, 3.8 kV;
heated capillary temperature, 320C; sheath and auxiliary gas, nitro-
gen; sheath gas flow rate, 30.1 AU; aux gas flow rate, 12.0 AU) equip-
ped with a Nucleosil 120 RP ODS column (8 mm, 2 3 250 mm, Ma-
cherey-Nagel). For separation, a gradient of acetonitrile in water
(each containing 0.1% HCOOH) ranging from 0% acetonitrile to 50%
acetonitrile over 20 min was used, followed by elution with 100% ace-
tonitrile for 5 min and equilibration with 100% water (containing 0.1%
HCOOH) for 4 min; the flow rate was 0.2 ml min1. The collision-
induced dissociation (CID) spectra during the HPLC run were recorded
with collision energy of +25 eV, collision gas argon, and collision pres-
sure of 1.0 3 103 torr (133 mPa).
1H-NMR spectra were measured on an Avance 400 spectrometer
(Bruker, Karlsruhe, Germany) with CD3OD as solvent.
1H-NMR spec-
tral data (400 MHz; CD3OD; br, broad).
Novclobiocin 201
d 1.18 (s, 3H-600), 1.35 (s, 3H-700), 2.26 (s, 3H-7 and 3H-8), 2.29 (s, 3H-
600 0 ), 3.52 (s, 3H-800), 3.72 (d, J = 10.3 Hz, H-400), 4.34 (br s, H-200), 5.70
(dd, J1 = 10.3 Hz, J2 = 3.3 Hz, H-3
00), 5.72 (br s, H-100), 5.93 (d, J = 3.7 Hz,
H-400 0 ), 6.90 (d, J = 3.7 Hz, H-300 0), 7.31 (d, J = 8.8 Hz, H-60), 7.63 (s, H-2
and H-6), 7.88 (d, J = 8.8 Hz, H-50).
MS: 657.3 ([M+H]+, Cl35), 659.3 ([M+H]+, Cl37), 282.1 [sugar+pyrrole
unit]+, 149.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 3.8 mg.evier Ltd All rights reserved
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d 1.17 (s, 3H-600), 1.38 (s, 3H-700), 2.26 (s, 3H-7 and 3H-8), 2.30 (s,
3H-600 0), 3.56 (d, J = 9.6 Hz, H-400), 3.65 (s, 3H-800), 4.44 (dd, J1 = 9.6
Hz, J2 = 2.8 Hz, H-3
00), 5.41 (br s, H-200), 5.82 (br s, H-100), 5.95 (d,
J = 3.4 Hz, H-400 0), 6.90 (d, J = 3.4 Hz, H-300 0), 7.31 (d, J = 6.1 Hz,
H-60), 7.62 (s, H-2 and H-6), 7.85 (d, J = 6.1 Hz, H-50 ).
MS: 657.3 ([M+H]+, Cl35), 659.1 ([M+H]+, Cl37), 282.0 [sugar+pyrrole
unit]+, 149.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 3.1 mg.
Novclobiocin 203
d 1.20 (s, 3H-600), 1.37 (s, 3H-700), 2.27 (s, 3H-7 and 3H-8), 2.29 (s,
3H-600 0), 3.51 (s, 3H-800), 3.69 (d, J = 9.9 Hz, H-400), 4.24 (br s, H-200),
5.59 (dd, J1 = 9.9 Hz, J2 = 2.2 Hz, H-3
00), 5.63 (br s, H-100), 5.94 (d,
J = 3.5 Hz, H-400 0), 6.90 (d, J = 3.5 Hz, H-300 0), 7.07 (overlapping signals,
J is not determinable, H-80 and H-60), 7.63 (s, H-2 and H-6), 7.90
(d, J = 6.8 Hz, H-50).
MS: 623.3 [M+H]+, 282.1 [sugar+pyrrole unit]+, 149.0 [Ring A ana-
log]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 3.0 mg.
Novclobiocin 217
d 0.97 (t, J = 7.4 Hz, 3H-9), 1.19 (s, 3H-600), 1.37 (s, 3H-700), 1.66 (sext.,
J = 7.4 Hz, 2H-8), 2.29 (s, 3H-600 0), 2.34 (s, 3H-80), 2.63 (t, J = 7.4 Hz,
2H-7), 3.53 (s, 3H-800), 3.71 (d, J = 10.0 Hz, H-400), 4.28 (br s, H-200),
5.62 (d, J = 2.0 Hz, H-100), 5.67 (dd, J1 = 10.0 Hz, J2 = 3.2 Hz, H-300),
5.94 (d, J = 3.8 Hz, H-400 0), 6.83 (d, J = 8.6 Hz, H-5), 6.90 (d, J = 3.8
Hz, H-300 0), 7.21 (d, J = 8.8 Hz, H-60), 7.73 (d, J = 8.6 Hz, H-6), 7.79
(br s, H-2), 7.83 (d, J = 8.8 Hz, H-50).
MS: 651.4 [M+H]+, 370.1 [M-(sugar+pyrrole unit)]+, 282.1 [sugar+
pyrrole unit]+, 163.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 1.0 mg after the second feeding
step.
Novclobiocin 218
d 0.96 (t, J = 7.4 Hz, 3H-9), 1.19 (s, 3H-600), 1.42 (s, 3H-700), 1.65 (com-
plex and broad signal, J is not determinable, 2H-8), 2.28 (s, 3H-80 ), 2.29
(s, 3H-600 0), 2.62 (t, J = 7.4 Hz, 2H-7), 3.51 (d, J = 9.2 Hz, H-400), 3.63 (s,
3H-800), 4.41 (dd, J1 = 9.2 Hz, J2 = 3.2 Hz, H-300), 5.37 (t, J = 2.6 Hz,
H-200), 5.69 (d, J = 2.6 Hz, H-100), 5.94 (d, J = 3.8 Hz, H-400 0), 6.81 (d,
J = 8.4 Hz, H-5), 6.88 (d, J = 3.8 Hz, H-300 0), 7.15 (d, J = 8.8 Hz, H-60),
7.72 (d, J = 8.4 Hz, H-6), 7.78 (br s, H-2), 7.81 (d, J = 8.8 Hz, H-50).
MS: 651.4 [M+H]+, 370.2 [M-(sugar+pyrrole unit)]+, 282.1 [sugar+
pyrrole unit]+, 163.0 [Ring A analog]+.
The total yield of the compound was 0.28 mg after the second feed-
ing step.
Novclobiocin 225
d 1.19 (s, 3H-600), 1.36 (s, 3H-700), 2.29 (s, 3H-600 0), 2.34 (s, 3H-80), 3.40
(d, J = 6.4 Hz, 2H-7), 3.52 (s, 3H-800), 3.71 (d, J = 10.0 Hz, H-400), 4.28 (br
s, H-200), 5.03 (d, J = 10.0 Hz, H-9a trans), 5.07 (dd, J1 = 18.8 Hz, J2 = 1.2
Hz, H-9a cis), 5.62 (d, J = 1.6 Hz, H-100), 5.67 (dd, J1 = 10.0 Hz, J2 = 3.2
Hz, H-300), 5.94 (d, J = 3.6 Hz, H-400 0), 6.05 (m, H-8), 6.85 (d, J = 8.4 Hz,
H-5), 6.90 (d, J = 3.6 Hz, H-300 0 ), 7.20 (d, J = 8.8 Hz, H-60), 7.76 (d,
J = 8.4 Hz, H-6), 7.79 (s, H-2), 7.82 (d, J = 8.8 Hz, H-50).
MS: 649.3 [M+H]+, 368.1 [M-(sugar+pyrrole unit)]+, 282.1 [sugar+
pyrrole unit]+, 161.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.80 mg after the second feed-
ing step.
Novclobiocin 226
d 1.19 (s, 3H-600), 1.42 (s, 3H-700), 2.28 (s, 3H-80), 2.29 (s, 3H-600 0), 3.40
(d, J = 6.8 Hz, 2H-7), 3.51 (d, J = 9.0 Hz, H-400), 3.63 (s, 3H-800), 4.41 (dd,
J1 = 9.0 Hz, J2 = 3.2 Hz, H-3
00), 5.02 (d, J = 10.4 Hz, H-9a trans), 5.06
(dd, J1 = 17.2 Hz, J2 = 2.0 Hz, H-9a cis), 5.37 (t, J = 2.6 Hz, H-2
00),
5.69 (d, J = 2.6 Hz, H-100), 5.94 (d, J = 3.6 Hz, H-400 0 ), 6.03 (m, H-8),
6.84 (d, J = 8.4 Hz, H-5), 6.88 (d, J = 3.6 Hz, H-300 0), 7.16 (d,Chemistry & Biology 14, 95J = 8.8 Hz, H-60), 7.75 (d, J = 8.4 Hz, H-6), 7.79 (s, overlapping signal,
H-2), 7.81 (d, overlapping signal, J is not determinable, H-50).
MS: 649.3 [M+H]+, 368.2 [M-(sugar+pyrrole unit)]+, 282.4 [sugar+
pyrrole unit]+, 161.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.30 mg after the second feed-
ing step.
Novclobiocin 241
d 1.19 (s, 3H-600), 1.23 (d, J = 6.8 Hz, 3H-10 and 3H-11), 1.34 (s,
3H-700), 2.29 (s, 3H-600 0), 2.75 (sept., J = 6.8 Hz, H-9), 3.51 (s, 3H-800),
3.71 (d, J = 10.3 Hz, H-400), 4.35 (br s, H-200), 5.70 (br s, H-100), 5.71 (dd,
J1 = 10.3 Hz, J2 = 3.0 Hz, H-3
00), 5.94 (d, J = 3.6 Hz, H-400 0 ), 6.90 (d,
J = 3.6 Hz, H-300 0), 6.94 (d, J = 7.8 Hz, H-5), 7.21 (d, J = 7.8 Hz, H-60),
7.71 (d, J = 8.0 Hz, H-6), 7.88 (d, J = 7.8 Hz, H-50), 8.28 (s, H-2). These
data are consistent with those reported previously [5].
MS: 714.3 ([M+H]+, Cl35), 716.5 ([M+H]+, Cl37), 282.0 [sugar+pyrrole
unit]+, 107.9 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.77 mg after the second feed-
ing step.
Novclobiocin 281
d 1.20 (s, 3H-600), 1.35 (s, 3H-700), 2.29 (s, 3H-600 0), 3.51 (s, 3H-800), 3.71
(d, J = 10.4 Hz, H-400), 4.32 (br s, H-200), 5.65 (br s, H-100), 5.71 (dd,
J1 = 10.4 Hz, J2 = 3.2 Hz, H-3
00), 5.94 (d, J = 3.4 Hz, H-400 0 ), 6.90 (d,
J = 3.4 Hz, H-300 0), 6.94 (d, J = 8.2 Hz, H-5), 7.21 (d, J = 9.0 Hz, H-60),
7.85 (d, J = 8.2 Hz, H-6), 7.90 (d, J = 9.0 Hz, H-50), 8.19 (br s, H-2).
These data are consistent with those reported previously [5].
MS: 707.1 ([M+H]+, Cl35), 709.3 ([M+H]+, Cl37), 282.2 [sugar+pyrrole
unit]+, 108.2 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.01 mg after the second feed-
ing step.
Novclobiocin 314
d 1.20 (s, 3H-600), 1.36 (s, 3H-700), 2.29 (s, 3H-600 0), 2.33 (s, 3H-80 ), 3.52 (s,
3H-800), 3.70 (d, J = 9.9 Hz, H-400), 3.92 (s, 3H-7), 4.28 (t, J = 2.8 Hz,
H-200), 5.68 (dd, J1 = 9.9 Hz, J2 = 3.0 Hz, H-300), 5.60 (d, J = 2.8 Hz,
H-100), 5.94 (d, J = 4.1 Hz, H-400 0), 6.84 (d, J = 8.1 Hz, H-5), 6.90 (d,
J = 4.1 Hz, H-300 0), 7.13 (d, J = 9.1 Hz, H-60), 7.54 (dd, J1 = 8.1 Hz,
J2 = 2.0 Hz, H-6), 7.64 (d, J = 2.0 Hz, H-2), 7.83 (d, J = 9.1 Hz, H-5
0).
MS: 639.3 [M+H]+, 358.1 [M-(sugar+pyrrole unit)]+, 282.1 [sugar+
pyrrole unit]+, 151.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.52 mg after the second feed-
ing step.
Novclobiocin 371
d 1.20 (s, 3H-600), 1.35 (s, 3H-700), 2.30 (s, 3H-600 0), 2.51 (s, 3H-7), 3.51 (s,
3H-800), 3.71 (d, J = 10.0 Hz, H-400), 4.34 (br s, H-200), 5.69 (br s, H-100),
5.72 (dd, J1 = 10.0 Hz, J2 = 3.0 Hz, H-3
00), 5.94 (d, J = 3.8 Hz, H-400 0 ),
6.91 (d, J = 3.8 Hz, H-300 0), 7.19 (d, J = 8.4 Hz, H-60), 7.28 (d,
J = 8.0 Hz, H-2 and H-6), 7.89 (d, J = 8.4 Hz, H-50), 7.92 (d, J = 8.1 Hz,
H-3 and H-5).
MS: 659.3 ([M+H]+, Cl35), 661.3 ([M+H]+, Cl37), 282.1 [sugar+pyrrole
unit]+, 151.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.81 mg.
Novclobiocin 372
d 1.18 (s, 3H-600), 1.38 (s, 3H-700), 2.30 (s, 3H-600 0), 2.52 (s, 3H-7), 3.55 (d,
J = 9.7 Hz, H-400), 3.64 (s, 3H-800), 4.45 (dd, J1 = 9.7 Hz, J2 = 3.3 Hz,
H-300), 5.39 (br s, H-200), 5.78 (br s, H-100), 5.95 (d, J = 3.4 Hz, H-400 0),
6.89 (d, J = 3.4 Hz, H-300 0), 7.19 (d, J = 8.8 Hz, H-600), 7.31 (d, J = 8.3 Hz,
H-2 and H-6), 7.88 (d, J = 8.8 Hz, H-50), 7.93 (d, J = 8.3 Hz, H-3 and
H-5).
MS: 659.5 ([M+H]+, Cl35), 281.8 [sugar+pyrrole unit]+.
The total yield of the compound was 0.05 mg.
Novclobiocin 386
d 1.18 (s, 3H-600), 1.36 (s, 3H-700), 2.19 (s, 3H-7), 2.29 (s, 3H-600 0), 2.34 (s,
3H-80), 3.52 (s, 3H-800), 3.71 (d, J = 9.8 Hz, H-400), 4.29 (t, J = 1.4 Hz,5–967, August 2007 ª2007 Elsevier Ltd All rights reserved 965
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Mutasynthetic Production of Modified AminocoumarinsH-200), 5.62 (d, J = 1.4 Hz, H-100), 5.67 (dd, J1 = 9.8 Hz, J2 = 2.8 Hz, H-300),
5.94 (d, J = 3.4 Hz, H-400 0), 6.72 (d, J = 9.2 Hz, H-5), 6.90 (d,
J = 3.4 Hz, H-300 0), 7.22 (d, J = 9.4 Hz, H-60), 7.67 (d, J = 9.2 Hz, H-6),
7.70 (br s, H-2), 7.83 (d, J = 9.4 Hz, H-50).
MS: 622.3 [M+H]+, 341.2 [M-(sugar+pyrrole unit)]+, 282.1 [sugar+
pyrrole unit]+, 134.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.48 mg after the second feed-
ing step.
Novclobiocin 387
d 1.19 (s, 3H-600), 1.41 (s, 3H-700), 2.19 (s, 3H-7), 2.28 (s, 3H-80), 2.29 (s,
3H-600 0), 3.51 (d, J = 8.8 Hz, H-400), 3.63 (s, 3H-800), 4.41 (dd, J1 = 8.8 Hz,
J2 = 2.8 Hz, H-3
00), 5.37 (t, J = 3.2 Hz, H-200), 5.69 (d, J = 2.4 Hz, H-100),
5.94 (d, J = 3.8 Hz, H-400 0), 6.71 (d, J = 8.4 Hz, H-5), 6.88 (d, J = 3.8 Hz,
H-300 0), 7.16 (d, J = 8.8 Hz, H-60 ), 7.66 (d, J = 8.4 Hz, H-6), 7.70 (br s,
H-2), 7.81 (d, J = 8.8 Hz, H-50 ).
MS: 622.3 [M+H]+, 341.1 [M-(sugar+pyrrole unit)]+, 282.2 [sugar+
pyrrole unit]+, 134.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.24 mg after the second feed-
ing step.
Novclobiocin 601
d 1.20 (s, 3H-600), 1.35 (s, 3H-700), 2.29 (s, 3H-600 0 ), 3.52 (s, 3H-800), 3.72
(d, J = 10.0 Hz, H-400), 4.33 (br s, H-200), 5.71 (overlapping signals, J is
not determinable, H-100 and H-300), 5.94 (d, J = 3.4 Hz, H-400 0 ), 6.90 (d,
J = 3.4 Hz, H-300 0 ), 7.28 (d, J = 8.8 Hz, H-60 ), 7.48 (t, J = 7.2 Hz, H-3
and H-5), 7.57 (t, J = 6.8 Hz, H-4), 7.91 (d, J = 8.8 Hz, H-50), 8.02 (d,
J = 7.2 Hz, H-2 and H-6).
MS: 613.2 ([M+H]+, Cl35), 615.3 ([M+H]+, Cl37), 332.1 [M-(sugar+pyr-
role unit)]+, 282.1 [sugar+pyrrole unit]+, 105.0 [Ring A analog]+, 108.0
[C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.36 mg.
Novclobiocin 602
d 1.18 (s, 3H-600), 1.38 (s, 3H-700), 2.30 (s, 3H-600 0 ), 3.56 (d, J = 9.4 Hz,
H-400), 3.64 (s, 3H-800), 4.44 (dd, J1 = 9.4 Hz, J2 = 3.2 Hz, H-300), 5.40
(t, J = 2.4 Hz, H-200), 5.82 (d, J = 1.6, H-100), 5.95 (d, J = 3.4 Hz,
H-400 0), 6.89 (d, J = 3.4 Hz, H-300 0), 7.30 (d, J = 9.0 Hz, H-60), 7.50 (t,
J = 7.4 Hz, H-3 and H-5), 7.58 (t, J = 7.4 Hz, H-4), 7.89 (d, J = 9.0 Hz,
H-50 ), 8.02 (d, J = 7.4 Hz, H-2 and H-6).
MS: 613.2 ([M+H]+, Cl35), 615.4 ([M+H]+, Cl37), 282.2 [sugar+pyrrole
unit]+, 104.9 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 1.07 mg.
Novclobiocin 603
d 1.20 (s, 3H-600), 1.37 (s, 3H-700), 2.29 (s, 3H-600 0 ), 3.51 (s, 3H-800), 3.69
(d, J = 9.6 Hz, H-400), 4.24 (br s, H-200), 5.59 (dd, J1 = 9.6 Hz, J2 = 2.8 Hz,
H-300), 5.64 (br s, H-100), 5.94 (d, J = 3.0 Hz, H-400 0 ), 6.90 (d, J = 3.0 Hz,
H-300 0), 7.07 (br s, H-60 and H-80), 7.51 (t, J = 7.0 Hz, H-3 and H-5), 7.59
(t, J = 7.0 Hz, H-4), 7.93 (d, J = 9.2 Hz, H-50), 8.02 (d, J = 7.0 Hz, H-2 and
H-6).
MS: 579.2 [M+H]+, 282.1 [sugar+pyrrole unit]+, 105.0 [Ring A ana-
log]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.74 mg.
Novclobiocin 604
d 1.20 (s, 3H-600), 1.36 (s, 3H-700), 2.29 (s, 3H-600 0), 2.34 (s, 3H-80), 3.52 (s,
3H-800), 3.70 (d, J = 9.8 Hz, H-400), 4.27 (t, J = 3.2 Hz, H-200), 5.60 (d,
J = 1.6 Hz, H-100), 5.68 (dd, J1 = 9.8 Hz, J2 = 2.8 Hz, H-300), 5.94 (d,
J = 3.4 Hz, H-400 0), 6.90 (d, J = 3.4 Hz, H-300 0), 7.14 (d, J = 9.0 Hz,
H-60 ), 7.46 (t, J = 7.4 Hz, H-3 and H-5), 7.52 (t, J = 7.4 Hz, H-4), 7.84
(d, J = 9.0 Hz, H-50), 8.02 (d, J = 7.4 Hz, H-2 and H-6).
MS: 593.2 [M+H]+, 312.1 [M-(sugar+pyrrole unit)]+, 282.1 [sugar+
pyrrole unit]+, 105.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.07 mg after the second feed-
ing step.966 Chemistry & Biology 14, 955–967, August 2007 ª2007 ElseNovclobiocin 701
d 1.17 (s, 3H-600), 1.36 (s, 3H-700), 2.29 (s, 3H-600 0), 3.51 (s, 3H-800), 3.72
(d, J = 9.8 Hz, H-400), 4.34 (br s, H-200), 5.68 (dd, J1 = 9.8 Hz, J2 = 2.4 Hz,
H-300), 5.71 (br s, H-100), 5.94 (d, J = 3.4 Hz, H-400 0 ), 6.90 (d, J = 3.4 Hz, H-
300 0 ), 7.01 (d, J = 15.3 Hz, H-1), 7.29 (d, J = 8.2 Hz, H-60), 7.39 (m, over-
lapping signals, H-5, H-6, and H-7), 7.60 (d, J = 6.8 Hz, H-4 and H-8),
7.71 (d, J = 15.3 Hz, H-2), 7.89 (d, J = 8.2 Hz, H-50).
MS: 639.5 ([M+H]+, Cl35), 641.6 ([M+H]+, Cl37), 357.9 [M-(sugar+pyr-
role unit)]+, 282.0 [sugar+pyrrole unit]+, 131.0 [Ring A analog]+, 108.0
[C6H6NO = pyrrole unit]
+.
The total yield of the compound was 4.0 mg. The yield obtained by
the two-stage feeding procedure was 0.18 mg after the second feed-
ing step.
Novclobiocin 702
d 1.17 (s, 3H-600), 1.38 (s, 3H-700), 2.30 (s, 3H-600 0), 3.64 (s, 3H-800), 3.56
(d, J = 9.6 Hz, H-400), 5.39 (br s, H-200), 4.44 (dd, J1 = 9.6 Hz, J2 = 3.3 Hz,
H-300), 5.79 (br s, H-100), 5.95 (d, J = 3.5 Hz, H-400 0), 6.89 (d, J = 3.5 Hz,
H-300 0 ), 6.98 (d, J = 16.4 Hz, H-1), 7.27 (d, J = 8.5 Hz, H-60), 7.39 (t, over-
lapping signals, J = 7.1 Hz, H-5, H-6, and H-7), 7.62 (d J = 7.1 Hz, H-4
and H-8), 7.69 (dd, J1 = 16.4 Hz, J2 = 1.3 Hz,, H-2), 7.89 (d, J = 8.5 Hz,
H-50).
MS: 639.2 ([M+H]+, Cl35), 642.2 ([M+H]+, Cl37), 282.2 [sugar+pyrrole
unit]+, 131.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.67 mg.
Novclobiocin 703
d 1.19 (s, 3H-600), 1.36 (s, 3H-700), 2.29 (s, 3H-600 0), 2.33 (s, 3H-80), 3.52
(s, 3H-800), 3.70 (d, J = 9.8 Hz, H-400), 4.27 (t, J = 2.2 Hz, H-200), 5.59 (d,
J = 2.2 Hz, H-100), 5.68 (dd, J1 = 9.8 Hz, J2 = 2.8 Hz, H-300), 5.94 (d,
J = 3.8 Hz, H-400 0), 6.89 (d, J = 14.0 Hz, H-1), 6.90 (d, J = 3.8 Hz, H-
300 0 ), 7.14 (d, J = 8.0 Hz, H-60), 7.38 (t, overlapping signals, J = 7.4 Hz,
H-5, H-6, and H-7), 7.60 (d, J= 7.4 Hz, H-4 and H-8), 7.62 (d, J= 14.0 Hz,
H-2), 7.83 (d, J = 8.0 Hz, H-50).
MS: 619.3 [M+H]+, 338.2 [M-(sugar+pyrrole unit)]+, 282.2 [sugar+
pyrrole unit]+, 131.0 [Ring A analog]+, 108.0 [C6H6NO = pyrrole unit]
+.
The total yield of the compound was 0.15 mg after the second feed-
ing step.
Novclobiocin 731
d 1.19 (s, 3H-600), 1.35 (s, 3H-700), 2.29 (s, 3H-600 0), 3.51 (s, 3H-800), 3.71
(d, J = 11.6 Hz, H-400), 3.90 (s, 3H-9), 4.33 (br s, H-200), 5.69 (br s, H-100),
5.71 (dd, J1 = 11.6 Hz, J2 = 2.0 Hz, H-3
00), 5.94 (d, J = 3.6 Hz, H-400 0 ),
6.75 (d, J = 15.8 Hz, H-1), 6.80 (d, J = 8.2 Hz, H-7), 6.90 (d, J = 3.6 Hz,
H-300 0 ), 7.07 (d, J = 8.2 Hz, H-8), 7.19 (br s, H-4), 7.23 (d, J = 8.8 Hz,
H-60), 7.57 (d, J = 15.8 Hz, H-2), 7.90 (d, J = 8.8 Hz, H-50).
MS: 685.3 ([M+H]+, Cl35), 687.1 ([M+H]+, Cl37), 404.1 [M-(sugar+pyr-
role unit)]+, 282.1 [sugar+pyrrole unit]+, 177.0 [Ring A analog]+, 108.0
[C6H6NO = pyrrole unit]
+.
The total yield of the compound was 1.1 mg.
Determination of Minimum Inhibitory Concentrations
The broth microdilution procedure recommended by the National
Committee for Clinical Laboratory Standards [30] was used for the de-
termination of the minimum inhibitory concentrations (MICs). All test
strains were obtained from the bacterial collection of Basilea Pharma-
ceutica AG (Basel, Switzerland). The MICs were determined as
described previously [16]. For testing, the aminocoumarins were
dissolved in DMSO. The maximum final concentration of DMSO in
the assays was 2% (v/v).
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